Literature DB >> 10878202

Hypoparathyroidism unmasked by alendronate.

A S Kashyap1, S Kashyap.   

Abstract

The case of an elderly woman is reported in whom alendronate, given for osteoporosis, led to severe hypocalcaemia a few days after starting the drug treatment. This was caused by the unmasking of previously unrecognised hypoparathyroidism.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10878202      PMCID： PMC1741632          DOI： 10.1136/pmj.76.897.417

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  5 in total

1.  Seizures after alendronate.

Authors:  Richard J Maclsaac; Ego Seeman; George Jerums
Journal:  J R Soc Med       Date:  2002-12       Impact factor: 5.344

Review 2.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 3.  Use of highly potent bisphosphonates in the treatment of osteoporosis.

Authors:  Michael McClung
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

4.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.

Authors:  Natalie E Cusano; Naim M Maalouf; Patty Y Wang; Chiyuan Zhang; Serge C Cremers; Elizabeth M Haney; Douglas C Bauer; Eric S Orwoll; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

5.  Hypoparathyroidism: what is the best calcium carbonate supplementation intake form?

Authors:  Loraine Gollino; Maria Fernanda Giovanetti Biagioni; Nathalia Regina Sabatini; José Vicente Tagliarini; José Eduardo Corrente; Sérgio Alberto Rupp de Paiva; Gláucia Maria Ferreira da Silva Mazeto
Journal:  Braz J Otorhinolaryngol       Date:  2017-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.